Literature DB >> 2649132

Prognosis of conjunctival melanomas in relation to histopathological features.

U Fuchs1, T Kivelä, K Liesto, A Tarkkanen.   

Abstract

Twenty-six patients (age 29-85 years) with primary malignant melanoma of the conjunctiva were analysed for usefulness of various histopathological and immunohistochemical features of the primary, recurrent and metastatic tumours in evaluating their prognosis. The mean follow-up time was 5.5 years, ranging from 8 months to 17 years. Eight patients developed metastases and seven have died. The mean time from diagnosis to death due to metastasis was 3.8 years (range 1-6 years). The site of the primary tumour seemed to be most closely correlated to high metastatic risk. Only two of the sixteen limbal melanomas metastasised, whereas two of the four bulbar, all three tarsal and the only diffuse primary tumour caused metastatic disease. Two of the metastasising primary tumours were less than 1.5 mm thick, but all exceeded 0.8 mm in thickness. The mitotic rate, the amount of inflammatory infiltrate, the cell type or the presence of adjacent intraepithelial involvement did not obviously correlate to treatment outcome. Furthermore, the expression of S-100 protein and neuron-specific enolase (NSE), both suggested to be prognostic indicators in cutaneous melanoma, did not correlate to the tendency of the conjunctival melanomas to recur or metastasise.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649132      PMCID: PMC2246983          DOI: 10.1038/bjc.1989.55

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

1.  NAEVI AND MELANOMATA OF THE CONJUNCTIVA.

Authors:  B JAY
Journal:  Br J Ophthalmol       Date:  1965-04       Impact factor: 4.638

2.  Histopathology of enucleated intraocular melanomas irradiated with cobalt and ruthenium plaques.

Authors:  U Fuchs; T Kivelä; A Tarkkanen; L Laatikainen
Journal:  Acta Ophthalmol (Copenh)       Date:  1988-06

3.  S-100 protein: a prognostic indicator in cutaneous malignant melanoma?

Authors:  N M Kernohan; R Rankin
Journal:  Histopathology       Date:  1987-12       Impact factor: 5.087

4.  Differential distribution of immunoreactive S100-alpha and S100-beta proteins in normal nonnervous human tissues.

Authors:  H Haimoto; S Hosoda; K Kato
Journal:  Lab Invest       Date:  1987-11       Impact factor: 5.662

5.  A monoclonal antibody against neuron-specific enolase. Immunohistochemical comparison with a polyclonal antiserum.

Authors:  P Thomas; H Battifora; G L Manderino; J Patrick
Journal:  Am J Clin Pathol       Date:  1987-08       Impact factor: 2.493

6.  Detection of cytoplasmic S-100 protein in primary and metastatic intraocular melanomas.

Authors:  A J Cochran; G N Holland; D R Wen; H R Herschman; W R Lee; R Y Foos; B R Straatsma
Journal:  Invest Ophthalmol Vis Sci       Date:  1983-08       Impact factor: 4.799

7.  The value of S-100 immunostaining as a diagnostic tool in human malignant melanomas. A comparative study using S-100 and neuron-specific enolase antibodies.

Authors:  D R Springall; J Gu; D Cocchia; F Michetti; A Levene; M M Levene; P J Marangos; S R Bloom; J M Polak
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1983

8.  Enolase isoenzymes in uveal melanomas--a possible parameter of malignancy.

Authors:  J A Royds; I G Rennie; M A Parsons; W R Timperley; C B Taylor
Journal:  Br J Ophthalmol       Date:  1983-04       Impact factor: 4.638

9.  Immunohistochemical differentiation between histiocytic and lymphoid neoplasms.

Authors:  P G Isaacson; D B Jones
Journal:  Histochem J       Date:  1983-07

10.  Mayo Clinic experience with conjunctival melanomas.

Authors:  T J Liesegang; R J Campbell
Journal:  Arch Ophthalmol       Date:  1980-08
View more
  14 in total

1.  Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma.

Authors:  Henrike Wuestemeyer; Wolfgang Sauerwein; Daniel Meller; Pierre Chauvel; Andreas Schueler; Klaus-Peter Steuhl; Norbert Bornfeld; Gerasimos Anastassiou
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-23       Impact factor: 3.117

2.  Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population.

Authors:  J C Norregaard; N Gerner; O A Jensen; J U Prause
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-09       Impact factor: 3.117

3.  Conjunctival melanoma.

Authors:  A B Tullo; R Bonshek
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

4.  Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients.

Authors:  C L Shields
Journal:  Trans Am Ophthalmol Soc       Date:  2000

Review 5.  Rare variants of malignant melanoma.

Authors:  G W Milton; H M Shaw
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

6.  Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study.

Authors:  Gerasimos Anastassiou; Arnd Heiligenhaus; Nikos Bechrakis; Elisabeth Bader; Norbert Bornfeld; Klaus-Peter Steuhl
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

7.  Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions.

Authors:  S Keijser; G S Missotten; J M Bonfrer; D de Wolff-Rouendaal; M J Jager; R J W de Keizer
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

8.  Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases.

Authors:  A D Paridaens; D C Minassian; A C McCartney; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1994-04       Impact factor: 4.638

9.  Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases.

Authors:  P De Potter; C L Shields; J A Shields; H Menduke
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

10.  Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva.

Authors:  P K Lommatzsch; R E Lommatzsch; I Kirsch; P Fuhrmann
Journal:  Br J Ophthalmol       Date:  1990-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.